Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia

Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia & lymphoma 2002, Vol.43 (1), p.149-151
Hauptverfasser:	Perz, Jolanta, Topaly, Julian, Fruehauf, Stefan, Hensel, Manfred, Ho, Anthony D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anti Cd20 Antibody Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal - toxicity Antibodies, Monoclonal, Murine-Derived Antigens, CD20 - metabolism Antineoplastic Agents - standards Antineoplastic Agents - therapeutic use Antineoplastic Agents - toxicity B-cell Chronic Lymphocytic Leukemia (B-CLL) B-cell Prolymphocytic Leukemia (B-PLL) Biomarkers - analysis Cd20-expression Disease-Free Survival Drug Evaluation Flow Cytometry Humans Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Leukemia, Prolymphocytic - diagnosis Leukemia, Prolymphocytic - drug therapy Leukemia, Prolymphocytic - mortality Male Middle Aged Monoclonal Antibody Rituximab Salvage Therapy Survival Rate Therapeutic Equivalency Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!